Contains Nonbinding Recommendations

Guidance on Duloxetine Hydrochloride

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Duloxetine Hydrochloride

Form/Route: Delayed Release Pellets Capsule/ Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover *in-vivo*
   Strength: 60 mg
   Subjects: Normal healthy males and females, general population.
   Additional Comments: Females should not be pregnant, and if applicable, should practice abstention or contraception during the study. Due to the need to maintain the enteric coating, the subjects in a BE study should be advised not to crush or chew the enteric coated pellets.

---

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover *in-vivo*
   Strength: 60 mg
   Subjects: Normal healthy males and females, general population.
   Additional comments: Please see above

Analytes to measure (in appropriate biological fluid): Duloxetine in plasma

Bioequivalence based on (90% CI): Duloxetine

Waiver request of in-vivo testing: 20 mg, 30 mg based on (i) acceptable bioequivalence studies on the 60 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.